May 12, 2025, 20:14

Cancer Grand Challenge: The Dark Proteome

This challenge invites global research teams to uncover the origins, functions, and therapeutic potential of the “dark proteome”—a group of proteins not derived from known coding sequences or DNA mutations. By understanding these unconventional proteins, the challenge aims to reveal new cancer vulnerabilities and develop immunologic or small molecule therapies that can be applied broadly across tumour types.

Eligibility Criteria:

Global, interdisciplinary research teams
Expertise in proteomics, immunology, RNA/protein biology, oncology, genetics, and analytical chemistry
Proposals must focus on proteins, not non-coding RNAs or splicing alterations

Funding Details:

Up to £20 million (USD 25 million) per team
Duration: Not specified

Deadline:

Expressions of Interest due: 18 June 2025

More Information:

Submit your Expression of Interest

cancer cancer biology Cancer Grand Challenge dark proteome immunotherapy microproteins novel antigens OncoDaily Oncology protein expression proteogenomics Synthetic Lethality tumour-selective targets

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research

In Memory of Bob Marley: His Battle with Melanoma and the Importance of Early Detection

Who From Oncology is Featured in TIME100 Health 2025?

FDA Announces Aggressive Timeline to Scale 1st AI-Assisted Scientific Review Pilot